Shanghai Henlius Biotech Inc. has announced that the China Securities Regulatory Commission (CSRC) has accepted its filing application for the H Share Full Circulation. This marks a significant step in the process of converting certain unlisted shares into H shares that will be listed and traded on the Main Board of the Hong Kong Stock Exchange. The acceptance of the application is part of the ongoing regulatory review required for this conversion and listing. The company will proceed with obtaining all necessary approvals and comply with relevant laws and regulations to finalize the process. Further announcements will be made as progress continues.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.